pro

linked2pay launches CustomerConnect to improve B2B invoice payments

linked2pay, a US-based payments technology provider, has...




pro

Free PC Camera Programs?




pro

Annoying Youtube (flash) problem.




pro

Hello Experts- I'm having bizarre sound problems...




pro

Compatibility:- Logitech C920 HD Pro USB 1080p Webcam and Windows 10







pro

Programs can completely ignore NTFS permissions




pro

Tencent launches social ecommerce mini program on WeChat

Hong-Kong-based conglomerate Tencent has rolled out Xiao’e Pinpin, a mini program for...




pro

Why These 2 Investment Professionals Say This Telemedicine Company Is One of Their Top Picks

Source: Streetwise Reports   04/28/2020

As the coronavirus pandemic has accelerated the move to telemedicine, two investment professionals are following CloudMD, a small cap rapidly expanding in Canada.

News Flash: On May 7, CloudMD announced that it is partnering with IDYA4 Corp. for it to resell the health technology firm's Livecare technology in the U.S.. Read more here.

News Flash: On May 4, CloudMD announced that it is partnering with Save-On-Foods grocery stores and Pure Integrative Pharmacy to pilot on demand, integrated virtual patient care through telemedicine kiosks placed in pharmacies' existing consult rooms. Read more here.

As people are avoiding going to doctor's offices and hospitals during the coronavirus pandemic, telemedicine has taken off. Two investment professionals, Bruce Campbell and Keith Schaefer, have called CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE), a small-cap Canadian telemedicine firm, a top pick.

Bruce Campbell, founder and portfolio manager of Stonecastle Investment Management, spoke about CloudMD on April 27 on BNN:

"The first top pick is CloudMD Software, a technological medical play. We've tried to look at opportunities that are really going to be able to take advantage of Covid and this is one of the ones that we think is; what they do is telemedicine.

"The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now." - Keith Schaefer

If you look back at a year ago, where everyone had to go to the doctor, and now all of the different provinces have opened up billing codes, so that now we don't have to go into a doctor's office. We can do a virtual doctor's visit and the doctor gets paid just like they do with an in-house appointment. Obviously with everything that has happened with this crisis, people really don't want to go into a doctor's office and they need a prescription renewal or something like that.

If you look at CloudMD's peers in the U.S., there is a company called Teladoc, which is a big U.S. company that does the same thing. Obviously, the size of the market is different, but the multiple it trades at is multiple times higher than where CloudMD is.

CloudMD is just starting to gain adoption. They started off here in BC, they have moved to Ontario, and they are going to be rolling out really across the country, so tons of opportunity for a company like this. They will probably change the way that we view our doctor and our healthcare visits going forward."

Keith Schaefer, editor and publisher of Oil & Gas Investments Bulletin, is also following CloudMD, and wrote:

"An entirely new—and highly profitable—industry is being borne out in 2020—TeleHealth. CloudMD Software & Services Inc. (DOC:CSE; DOCRF:OTCQB; 6PH:FSE) is my favorite way to play TeleHealth. It's growing quickly with over 100,000 patients registered on its app and over 3000 doctors in 8 provinces in its Electronic Medical Records—EMR—system. It has MULTIPLE revenue streams and it just moved into Canada's largest market—Ontario—setting up an even faster growth rate.

The recent spread of coronavirus is only accelerating this. Covid-19 has forever changed how we all will think about visiting a hospital or seeing our doctor. We really don't want to do that at all, if possible. It will have a very positive and long lasting impact on TeleHealth.

TeleHealth companies in Canada are getting paid more money for services than bricks-and-mortar clinics, and have a fraction of the costs. Doctors want more of it, patients want more of it, government wants more of it—and the Market REALLY wants more of it. Everybody wins here; there is no downside.

The rapid scale-up and profitability is key for investors.

CloudMD is established, growing quickly and trading at a fraction of its peers. The average multiple of competitors in the sector trade at 5-7x revenue, and CloudMD is trading way below that at 2.5x per revenue. But realize that the Canadian use of telemedicine is still just a fraction of where it is in the U.S—so the quick, early upside is even bigger.

The market desperately wants to own TeleHealth right now. I see CloudMD as the best way to do that in the junior sector (where the leverage is!).

For this stock to have a major run all that needs to happen is for institutional investors to wake-up to the fact that the company exists. That's happening now with the company entering the province of Ontario—which has 14.5 million people—over one-third of Canada's population.

CloudMD is a fully integrated health care company—kind of like a hospital-in-the-sky. They do have five bricks-and-mortar clinics, but they also own their own EMR—Electronic Medical Records—system that operates in eight provinces and is used by over 3,000 doctors and is supported by an in-house 25 person development team. They have their own CloudMD app—which has over 100,000 registered patients already.

The EMR gives CloudMD a recurring monthly revenue stream, which The Street loves. The app gives them high-margin fees from doctors, specialists and groups like massage therapists & counselors. These people are revenue, not costs. As I said, full hospital-in-the-sky. Multiple revenue sources with lower costs.

To schedule a virtual doctor's appointment all that a patient has to do is download the free CloudMD app and then arrange an appointment with one of the doctors. There is zero charge for the patient and they can see a doctor very quickly.

CloudMD can scale up the number of patients VERY quickly—and they are. Every aspect of healthcare that's very fractured and disjointed will now be in the one CloudMD ecosystem.
Everyone wins with this system. Patients, doctors, the medical system, society, even investors. Everyone.

Doctors who have signed up with CloudMD work remotely from home or wherever they are (like their winter home down south). The rapid scale-up potential excites me. CloudMD can add in unlimited number of doctors and patients—so it has a virtually unlimited ability to scale quickly with little incremental cost.

Profit margins are wide and there is no cap on the number of customers that can be handled.

After a patient has an appointment, CloudMD bills the government directly just like every bricks-and-mortar clinic in Canada does. CloudMD records 100% of the revenue and gets to keep 30% of the billing for every patient that is seen through telemedicine, which is actually 10% more than what a bricks-and-mortar clinic receives. That is because the governments are trying to push TeleHealth. The doctor gets the other 70% and doesn't have to deal with any headaches of commuting or running a business.

Without the overhead of a bricks-and-mortar clinic, AND more revenue, CloudMD will be much more profitable than traditional healthcare stocks. Faster scale, more cash flow. And they just entered Canada's largest market. This is the right stock in the right market at the right time. That's the great thing about this business model. It's very scalable, very easy, and it grows very quickly.

CloudMD has been growing its recurring SAAS (Software-as-a-Service) revenue by 30% YoY with its EMR system. But this year the company is expecting that doctor growth to be much much higher—with a new full time sales team and the coronavirus pandemic. SaaS revenue is highly lucrative!

The jumping off point for TeleHealth is here and I think CloudMD is the best pure-play TeleHealth stock right now."

Read Keith Schaefer's entire article here.

Watch Bruce Campbell of StoneCastle Investments share his top picks: CloudMD, Lightspeed and Viemed.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Keith Schaefer: I, or members of my immediate household or family, own shares of the following companies mentioned in this article: CloudMD. I personally am, or members of my immediate household or family are, paid by the following companies mentioned in this article: CloudMD. My company has a financial relationship with the following companies mentioned in this article: None. Additional disclosures are listed below.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with CloudMD. Please click here for more information. An affiliate of Streetwise Reports is conducting a digital media marketing campaign for this article on behalf of CloudMD. Please click here for more information.
3) Statements and opinions expressed are the opinions of the author and not of Streetwise Reports or its officers. The author is wholly responsible for the validity of the statements. The author was not paid by Streetwise Reports for this article. Streetwise Reports was not paid by the author to publish or syndicate this article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
4) This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of CloudMD, a company mentioned in this article.

Additional Disclosures

Keith Schaefer Disclosures:
CloudMD has reviewed and sponsored this article. The information in this newsletter does not constitute an offer to sell or a solicitation of an offer to buy any securities of a corporation or entity, including U.S. Traded Securities or U.S. Quoted Securities, in the United States or to U.S. Persons. Securities may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and applicable U.S. state securities laws or pursuant to an exemption therefrom. Any public offering of securities in the United States may only be made by means of a prospectus containing detailed information about the corporation or entity and its management as well as financial statements. No securities regulatory authority in the United States has either approved or disapproved of the contents of any newsletter.

Keith Schaefer is not registered with the United States Securities and Exchange Commission (the "SEC"): as a "broker-dealer" under the Exchange Act, as an "investment adviser" under the Investment Advisers Act of 1940, or in any other capacity. He is also not registered with any state securities commission or authority as a broker-dealer or investment advisor or in any other capacity.

Bruce Campbell, Stonecastle Investment Management:
A guest firm/affiliate holds a position in CloudMD. There is no guest position held, members of his household do not hold positions and CloudMD is not an investment banking client.

( Companies Mentioned: DOC:CSE; DOCRF:OTCQB; 6PH:FSE, )




pro

BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

Source: Streetwise Reports   04/22/2020

The ways in which Moderna is to use the funds are explained and an update on its coronavirus vaccine is provided in a ROTH Capital Partners report.

In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna Inc. (MRNA:NASDAQ) $483 million in funding, in part for development of its COVID-19 vaccine, mRNA-1273.

Rahimi discussed how Massachusetts-based Moderna will use the funds, which will be provided in tranches to reach certain milestones.

Half of the $483 million award will be used to help cover clinical development costs of mRNA-1273, from trial operations to the filing of a biologics license application.

Currently, the vaccine is in Phase 1 in the clinic. Recently, the biopharma decided to add to the study a cohort of patients aged 51 years and up, which "will be key for demonstrating mRNA-1273's safety and immunogenicity in this vulnerable population," Rahimi noted.

The analyst explained that for mRNA-1273 to advance to Phase 2, the results from Phase 1 must be optimal. The data must demonstrate the vaccine is safe and tolerable. They must show that the vaccine produced a sufficient number of neutralizing antibodies, crucial for stopping viral replication and proving the vaccine's method of action. Phase 1 safety data from the group aged 18–55 years are expected in spring followed by immunogenicity results, likely in mid-July or early August.

Rahimi relayed that as soon as safety data are available, Moderna plans to launch a Phase 2 study of mRNA-1273 rather than wait for the remaining results to become available, according to CEO Stéphane Bancel.

"Pending favorable safety data from Phase 1, we point out that a potential Phase 2 study would enroll hundreds of patients, and that the BARDA funding could potentially allow Moderna to pursue trials in patient populations who are at greater risk, such as patients who have underlying comorbidities, those who are overweight and patients with cancer," commented Rahimi.

Moderna will spend the second half of the $483 million BARDA funding on the engineering and optimization work required to scale up the manufacturing of its messenger RNA (mRNA).

"With the current focus on SARS-CoV-2 and mRNA-1273, Moderna was now able to present BARDA its strategic plans (amount, time and people) of how to be ready for commercial launch," wrote Rahimi. "This preparation was likely helpful in expediting discussions with BARDA and awarding of the grant."

Also regarding mRNA production, Ginkgo Bioworks, a company with expertise in organism biology and genetically engineering bacteria to replace certain industrial applications, is helping Moderna optimize certain parts of the process.

Rahimi, who is closely tracking COVID-19 data, highlighted that April 18 was the first day in five on which the daily death tally, 1,867, was less than that predicted by Dr. Christopher Murray's model, 2,194.

ROTH has a Buy rating on Moderna.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Moderna Inc., Company Note, April 19, 2020

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Within the last twelve months, ROTH has received compensation for investment banking services from Moderna, Inc.

ROTH makes a market in shares of Moderna, Inc. and as such, buys and sells from customers on a principal basis.

Within the last twelve months, ROTH has managed or co-managed a public offering for Moderna, Inc.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: MRNA:NASDAQ, )




pro

IDEX Biometrics to provide fingerprint sensors for Zwipe

IDEX Biometrics has announced it will provide its...




pro

ECOMMPAY offer 0 percent on card processing fees during COVID-19 pandemic

Payment service provider and direct card acquirer ECOMMPAY have...




pro

Stripe introduces global card support, card self-issuing, and revenue engine improvements

US-based payment technology company Stripe has introduced global...




pro

ACI provides new payment features within ACI Issuer

US-based payment systems company ACI has developed a...




pro

Smart Payment Association promotes an Instant Payment Card solution




pro

Thumbzup, First Distribution partner to process card transactions in Azure

South-Africa based PSP Thumbzup and cloud service distributor



pro

Solar Energy Firm Signs Large Deal for New York Project, 12–15 Times Its Average Size

This project, along with two other new projects, increases the company's order backlog by 65%.




pro

Mega Solar Project in Puerto Rico Moving Ahead

Greenbriar Capital has signed an agreement for the design and construction of the Caribbean's largest solar project.




pro

Can reserve networks protect coral reefs from climate change?

A new study has conducted a preliminary investigation into the design of reserves that would help protect coral reefs from climate change. The results indicate that, 15 per cent of coral reefs in the Bahamas, the study area, would be able to withstand rising temperature, and would therefore be appropriately placed in reserves.




pro

Green Economy promotes economic and social development

Adopting the Green Economy approach will reap greater environmental, social and economic benefits, compared with a society that focuses on economic growth as the measure for future development, according to a recent UN report. Using two per cent of global GDP to ???green??? key sectors could be enough to trigger the transition towards a green economy.




pro

???Seascape???: a key influence on marine protected areas

New research has shed light on how fish respond to marine protected areas (MPAs). It suggests that seascape structure ??? the range of sea depths and habitat types included inside and outside the MPA ??? has a larger influence on changes in the abundance of fish than protection itself.




pro

CSR for water: progress towards sustainability

Access to water is often described as a basic human right, so rights violations may be committed where corporate activities interfere with individuals' access to water. Water supply is generally the responsibility of government, but recent Dutch research has suggested that corporate social responsibility (CSR) can have a significant impact on the sustainability of freshwater supply in countries with weak governance regimes.




pro

Sustainability programmes: eclectic toolboxes or clear roadmaps?

Sustainable consumption and production (SCP) programmes are frameworks to systemically develop sustainability. New research has analysed three national SCP programmes in the UK, Sweden and Finland and concluded that, rather than provide a strong roadmap for sustainability, they tend to be a toolbox of good but scattered initiatives.




pro

Reducing bycatch will not damage fishing industry profits

Bycatch (species caught unintentionally in fisheries) in some commercial marine fisheries is the main cause of death in some populations of seabirds, sea turtles, marine mammals, sharks and fish. New research has revealed that bycatch from tuna fishing can be reduced by using better equipment, without compromising industry profits. However, significant policy efforts are needed to monitor bycatch and enforce more sustainable fishing practices.




pro

Extreme weather warning system improves water management

A new study indicates that water management in the Netherlands uses a reliable warning system for extreme weather, which can incorporate wind and coastal surge level forecasts, as well as precipitation forecasts.




pro

Mediterranean MPA provides fish larvae for neighbouring areas

New research has found evidence that a small Marine Protected Area (MPA) in the Mediterranean has the potential to deliver larvae of some fish species to surrounding, non-protected areas. This is one of few studies to investigate this desired role of MPAs and its design could be used to evaluate current and future MPAs elsewhere.




pro

Improved fisheries management needed to maintain tuna stocks

Stricter management of fisheries is needed to prevent overexploitation and decline of tuna and their mackerel relatives, according to an international study. The researchers say fisheries managers have wrongly treated upper limits for catches as target levels for fishing, contributing to global declines and the threatened status of some species.




pro

Four key techniques to encouraging pro-environmental behaviour

A new analysis of how to encourage pro-environmental behaviour highlights four effective techniques: goal-setting, prompts or reminders, witnessing the behaviour of others and introducing new behaviours that correspond with existing beliefs.




pro

The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million to

The last two decades have seen a series of new construction waste policies management in Hong Kong. One of the most significant is an offsite construction waste sorting (CWS) programme which, since its implementation in 2006, has separated 5.11 million tonnes of construction waste into different materials. The researchers suggest that the study provides an important reference for other countries working to minimise construction waste.




pro

Plants provide ???green liver??? by removing water toxins

Blue-green algae, or ???aquatic cyanobacteria???, can produce harmful toxins and present a serious health hazard when they bloom in large numbers. Researchers from Germany have now identified plant species that could be used to sustainably treat water by removing such cyanobacterial toxins.




pro

Product design screening method helps reduce toxic materials in consumer goods

A recent study has described a simple method to screen the toxicity of materials used in consumer products. Using utility meter products as examples, the study found, for example, that stainless steel and polyvinyl chloride (PVC) had high toxicity potentials and suggests less toxic, but equally effective and priced, alternatives that could be used instead.




pro

Zero Waste Index proposed for improving city waste management

A new tool to improve the measurement of waste management performance has been presented by a recent study. The researchers applied it to three high consuming cities aspiring to ???zero waste???, finding San Francisco to be closer to achieving zero waste than Stockholm and Adelaide, due to its emphasis on reusing solid waste.




pro

Learning from experience: an evaluation of a UK Green Infrastructure project

The development of Green Infrastructure (GI) in a UK case study has been researched in a recent study. Some issues caused by an imbalance in stakeholder power and conflicting roles played by major stakeholders were identified with the project. Stakeholder participation is central to the concept of GI and the research reiterates the importance for those implementing GI to ensure that participation is effective and balanced.




pro

Surveyed professionals feel local authorities should have more influence in urban density

Density in the urban environment can encompass a multitude of factors such as population or dwelling density or the density of green areas. A new study surveyed professionals regarding how decisions on urban density are made, and has revealed that many feel that developers make most of these decisions, but that local authority planners should have more influence.




pro

Sustainability drivers identified for smaller businesses in European protected areas

Tourism businesses operating in protected conservation areas in Europe engage in a high number of sustainable practices, a recent survey of over 900 small-to-medium enterprises (SMEs) reveals. Reasons for their sustainable behaviour include cutting costs, improving company image and lifestyle choices.




pro

Sudden changes in marine ecosystems should be addressed through multi-targeted approach

The world’s marine ecosystems are at risk of sudden and damaging changes. The authors of a recent study say that co-ordinated management of the many drivers of marine changes, such as overfishing and pollution, is needed across international, national and local scales to help avoid the ‘regime shifts’ that affect ecosystem services and human wellbeing.




pro

Protecting seagrass from anchor damage: new recommendations

Damage caused by boats anchoring in seagrass meadows off the coast of Sardinia continues despite restrictions, new research shows. The study's authors provide a number of recommendations to help protect seagrass. These include creating special anchoring areas in seagrass-free locations, and limiting the number of boats that enter a marine protected area.




pro

Strong connections found between marine protected areas

Marine Protected Areas should be managed as integrated networks rather than isolated units because of the high degree of exchange between them, a new study suggests. The researchers found that the large majority of sea bream (Sparidae) and wrasse (Labridae) fish spawned in MPA study sites in the Mediterranean Sea were transported via currents to other MPAs and unprotected areas, highlighting their interconnected nature.




pro

Exploring the secrets to success in sustainable-technology demonstration projects

Demonstration projects can represent a critical intermediate step between research and development (R&D) and large-scale commercialisation; yet many involving new sustainable technologies fail. In order to map the internal and external factors that enable or prohibit demonstration projects from reaching their goals, a case study of 21 projects was conducted. Qualitative data collected from funding applications and interviews were analysed to identify key themes. Based on these findings, the study proposes a process model outlining the key activities for setting up a new demonstration project.




pro

Road and rail infrastructure threaten Sweden’s protected birds

In Sweden, 63% of areas designated as Special Protection Areas (SPAs) for endangered birds are impacted by major roads or train lines, according to a new study. The research showed that 126 000 hectares (ha), or 4.2% of the SPAs, fall within 1 km of a road or train line, leading to a predicted 1% loss in bird abundance. The problem is greater in the south of the country, where 25.8% of land designated as SPA falls within 1 km of a road or rail line, representing an estimated 4 to 7% reduction in birds’ abundance within SPAs.




pro

Routine monitoring of Mediterranean boats and marinas could help protect ecosystems from invasive alien species

A survey of over 600 private boats docked in marinas throughout the Mediterranean showed that 71% are carrying non-indigenous species. In certain cases, non-indigenous species can become ‘invasive’ and have enormous and long-lasting impacts on ecosystems. The findings suggest that a common monitoring strategy may be necessary to prevent further disruptions to natural ecosystems.




pro

Zero Waste Index proposed for improving city waste management

A new tool to improve the measurement of waste management performance has been presented by a recent study. The researchers applied it to three high consuming cities aspiring to ‘zero waste’, finding San Francisco to be closer to achieving zero waste than Stockholm and Adelaide, due to its emphasis on reusing solid waste.




pro

Consumer footprints for personal hygiene and cleaning products

A new study provides recommendations to reduce the environmental impact of personal hygiene and cleaning products on the environment. Researchers undertook life-cycle assessments of products including detergents, soaps and toilet cleaners, and compared their environmental footprints looking at different types of environmental damage.




pro

Low-carbon product design: look at the parts to improve the whole

Researchers have developed a method to identify the parts that contribute the most to a product's greenhouse gas (GHG) emissions and evaluate alternative design solutions. When applied to a LCD television, it showed that GHG emissions could be cut by 36 per cent by using alternative parts to those currently used.




pro

Embedding sustainability into the design of products and services

The qualities of sustainable design and the obstacles that Design for Sustainability (DfS) faces are explored by a new study which provides recommendations on how to overcome these challenges. It suggests that design education needs to change and provides advice on how to improve our understanding of consumer behaviour.




pro

Sustainable nanotechnology: a combined life cycle and risk assessment approach

As the development of nanomaterials increases, a recent study recommends combining life cycle analysis and risk assessment to improve our understanding of the potential environmental and human health impacts of products containing nanomaterials.




pro

How do consumers assess the eco-friendliness of food products?

A recent Swiss study compared consumer perceptions of the environmental friendliness of vegetables with the results of scientific assessments of the vegetables’ environmental impact. The two did not always tally and findings from this study can provide useful information for sustainable consumption campaigns.




pro

Green Infrastructure can promote economic development

A recent study has concluded that the green infrastructure concept has been successful in integrating green space policy with economic development policies in the north-west region of the UK, by emphasising the links between the economic benefits of green spaces and growth policies.